Antibodies to complementary peptides of thrombin or portions thereof
Disclosed are antibodies and antigen-binding fragments that bind to a complementary peptide having an amino acid sequence that is encoded by the complement of a nucleotide sequence encoding thrombin or a portion thereof. Such antibodies and antigen-binding fragments can be agonists or antagonists of thrombin receptor-mediated events. Also disclosed are methods of using the agonist antibodies and antigen-binding fragments of the invention to activate the non-proteolytically activated thrombin receptor (NPAR) in a subject in need of such treatment. In addition, methods of using the antagonist antibodies and antigen-binding fragments of the invention to inhibit activation of the NPAR in a subject in need of such treatment are disclosed.
1. An antibody or antigen-binding fragment thereof that binds to a complementary peptide, wherein said complementary peptide is encoded by the complement of a nucleotide sequence encoding a portion of thrombin, wherein said portion of thrombin is a thrombin receptor binding domain or a portion thereof; and wherein said thrombin receptor binding domain or portion thereof is a thrombin receptor binding domain having the amino acid sequence AGYKPDEGKRGDACEGDSGGPFV (SEQ ID NO:1).
2. The antibody or antigen-binding fragment of claim 1 , wherein said complementary peptide has the amino acid sequence KGSPTVTFTGIPCFPFIRLVTS (SEQ ID NO:3).
3. The antibody or antigen-binding fragment of claim 1 , wherein said antibody or antigen-binding fragment is an agonist antibody or antigen-binding fragment thereof.
4. The antibody or antigen-binding fragment of claim 1 , wherein said antibody or antigen-binding fragment is an antibody.
5. The antibody or antigen-binding fragment of claim 4 , wherein said antibody is a polyclonal antibody.
6. The antibody or antigen-binding fragment of claim 1 , wherein said antibody or antigen-binding fragment is a monoclonal antibody or an antigen-binding fragment thereof.
7. The antibody or antigen-binding fragment of claim 1 , wherein said antibody or antigen-binding fragment is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody and an antigen-binding fragment of any of the foregoing.
8. The antibody or antigen-binding fragment of claim 1 , wherein said antibody or antigen-binding fragment is an antigen-binding fragment.
9. The antibody or antigen-binding fragment of claim 8 , wherein said antigen-binding fragment is selected from the group consisting of an Fab fragment, an Fab′ fragment, an F(ab′) 2 fragment and an Fv fragment.
10. An isolated cell that produces an antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment binds to a complementary peptide encoded by the complement of a nucleotide sequence encoding a portion of thrombin, wherein said portion of thrombin is a thrombin receptor binding domain or a portion thereof, and wherein said thrombin receptor binding domain or portion thereof is a thrombin receptor binding domain having the amino acid sequence AGYKPDEGKRGDACEGDSGGPFV (SEQ ID NO:1).
11. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof and a pharmaceutically-acceptable carrier, wherein said antibody or antigen-binding fragment binds to a complementary peptide encoded by the complement of a nucleotide sequence encoding a portion of thrombin, wherein said portion of thrombin is a thrombin receptor binding domain or a portion thereof, and wherein said thrombin receptor binding domain or portion thereof is a thrombin receptor binding domain having the amino acid sequence AGYKPDEGKRGDACEGDSGGPFV (SEQ ID NO:1).